Alamast

Name: Alamast

What Is Pemirolast Ophthalmic?

Pemirolast is an anti-allergic medicine. It inhibits processes in the body that cause allergic symptoms after exposure to an allergen.

Pemirolast ophthalmic (for the eye) is used to treat prevent itching in the eyes caused by allergies.

Pemirolast ophthalmic should not be used to treat eye irritation caused by wearing contact lenses.

Pemirolast ophthalmic may also be used for purposes not listed in this medication guide.

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

You should not use pemirolast ophthalmic if you are allergic to it.

To make sure pemirolast ophthalmic is safe for you, tell your doctor if you have:

  • an untreated infection (bacterial, viral, or fungal) in your eye.

FDA pregnancy category C. It is not known whether pemirolast ophthalmic will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medicine.

It is not known whether pemirolast ophthalmic passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

Pemirolast ophthalmic should not be given to a child younger than 3 years old.

How supplied

ALAMAST® (pemirolast potassium ophthalmic solution) 0.1% is supplied as follows:

10 mL in a white, low density polyethylene bottle with a controlled dropper tip, and a white polyethylene screw cap.

NDC 68669-711-10 10 mL fill in 11 cc container

Storage

Store at 15°–25°C (59°–77°F).

Manufactured by: Santen Oy, PO Box 33, FIN-33721 Tampere, Finland. February 2005 Version. Marketed by: VISTAKON® Pharmaceuticals, LLC Jacksonville, FL 32256 USA. Licensed from Mitsubishi Pharma Corporation Japan. FDA revision date: 5/12/2005

Stability

Storage

Ophthalmic

Solution

15–25°C.1

Actions

  • Suppresses the release of mediators from cells involved in hypersensitivity reactions, including mast cells, and decreases chemotaxis and activation of eosinophils.1

  • Reportedly blocks calcium channels in mast cell membranes.1

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Pemirolast Potassium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Ophthalmic

Solution

0.1%

Alamast (with lauralkonium chloride)

Vistakon

Alamast Dosage and Administration

The recommended dose is one to two drops in each affected eye four times daily.

Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks).

Warnings

Contraindications

Hypersensitivity

Cautions

For ophthalmic use only

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

  • Contact lens–related irritation—Pemirolast should not be used to treat this condition

Who should not use pemirolast ophthalmic (alamast)?

Do not use pemirolast ophthalmic if you have a bacterial, viral, or fungal infection in your eye unless you are also receiving proper anti-infective treatment.

Pemirolast ophthalmic is in the FDA pregnancy category C. This means that it is not known whether pemirolast ophthalmic will harm an unborn baby. Do not use pemirolast ophthalmic without first talking to your doctor if you are pregnant.

It is not known whether pemirolast passes into breast milk. Do not use pemirolast ophthalmic without first talking to your doctor if you are breast-feeding a baby.

Pemirolast ophthalmic is not approved for use by children younger than 3 years of age.

  • Allergy Drugs: Prescription and OTC

Read the Alamast User Reviews »

© Alamast Patient Information is supplied by Cerner Multum, Inc. and Alamast Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

(web3)